Navigation Links
Neurocrine Biosciences Reports Third Quarter 2013 Results
Date:10/29/2013

s in 280 women with heavy uterine bleeding due to uterine fibroids.

VMAT2 UpdateThe Company has completed enrollment in Kinect 2, a Phase IIb study of its VMAT2 inhibitor, NBI-98854. This study is a 90 subject, placebo-controlled, double-blind, parallel-design, multiple-dose, six-week study assessing NBI-98854 in doses up to 75mg once-a-day against placebo in tardive dyskinesia patients with underlying mood disorders, schizophrenia and schizoaffective disorders, and gastrointestinal disorders. The primary endpoint is the Abnormal Involuntary Movement Scale (AIMS) at the end of the six weeks of dosing. The video AIMS will be scored by blinded central reviewers who are movement disorder neurologists. This study recently completed screening and randomization of subjects, and top-line data from this study is expected in December of 2013.

In 2014, the Company intends to initiate another clinical study of NBI-98854 in tardive dyskinesia patients. This study is currently in the design phase, and the results of the Kinect and Kinect 2 Studies will serve to inform the ultimate design of this clinical trial. The primary endpoint in this study will be the AIMS assessed by blinded central reviewers who are movement disorder neurologists.

The Company is currently completing two Phase I studies for NBI-98854 assessing drug-drug interactions as well as the impact of hepatic impairment on drug metabolism.

Additionally, the Company is conducting preclinical studies to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome. Upon successful completion of these preclinical studies, the Company anticipates entering Phase I and Phase II clinical studies in 2014.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 866-952
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2013 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
5. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Neurocrine Biosciences Reports Third Quarter 2012 Results
7. Neurocrine Biosciences Reports Second Quarter 2012 Results
8. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
9. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 A leading manufacturer of stainless ... to discuss its custom fabrication services today at INTERPHEX ... which launched just prior to the INTERPHEX event. The ... 22 and 23) at the Javits Center in New ... world’s largest and most innovative pharmaceutical and biotech firms ...
(Date:4/21/2015)... April 21, 2015 YourEncore, an ... life sciences, consumer products and food sciences industries ... the Alliance for Clinical Research Excellence and Safety ... for conducting clinical research, have partnered to speed ... , YourEncore brings to ACRES experts with ...
(Date:4/20/2015)... British Columbia and MENLO ... --  DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar ... developing and commercializing proven cancer therapies in new ... at the 106th Annual Meeting of the ... Meeting on the potential for its lead product ...
(Date:4/20/2015)... April 20, 2015 Orthobiologics are ... bone injuries. The orthobiologics market is a rewarding market, ... stakeholders. The global orthobiologics market report defines and segments ... The global orthobiologics market was valued at $5,712.4 million ... by 2019, at a CAGR of 6.7% from 2014 ...
Breaking Biology Technology:HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... , , PHILADELPHIA, July ... the Year, today announces the opening of two key new locations in ... 2010 growth plan. Digitas Health has experienced increased annual revenue growth of ... client brand wins over the past 12 months, and has received substantial ...
... , , EMERYVILLE, Calif., ... ) ( http://www.novabaypharma.com ), a clinical stage company developing non-antibiotic ... range of bacterial, viral and fungal infections, announced today that ... at the Jesup & Lamont 2009 Growth Stock Conference organized ...
... GAITHERSBURG, Md., July 27 Today GenVec, Inc. (Nasdaq: ... with the PATH Malaria Vaccine Initiative (MVI) to support the ... funding. This contract, valued at approximately $2 million, will continue ... preclinical feasibility studies of novel adenovirus-based vaccines. Based on the ...
Cached Biology Technology:Digitas Health Expands Adding Two Key Locations 2Digitas Health Expands Adding Two Key Locations 3Digitas Health Expands Adding Two Key Locations 4NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference 2NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference 3GenVec Expands Contract Supporting Malaria Vaccine Program 2GenVec Expands Contract Supporting Malaria Vaccine Program 3
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... CHAMPAIGN, Ill. A newly engineered yeast strain can ... produce ethanol, researchers report. The sugars are glucose, a ... xylose, a five-carbon sugar that has been much more ... made by combining, optimizing and adding to earlier advances, ...
... Society of Plant Biologists (ASPB) applauds Congressional reauthorization ... in 2007, the America Creating Opportunities to Meaningfully ... Act underscored the nation,s commitment to scientific research ... Among other provisions, the 2007 and 2010 bills ...
... An expert working group of the International Osteoporosis ... Chemistry and Laboratory Medicine (IFCC) has released a ... bone turnover markers (BTMs) in fracture risk prediction ... identifies research priorities and recommends that specific markers ...
Cached Biology News:Team overcomes major obstacles to cellulosic biofuel production 2Team overcomes major obstacles to cellulosic biofuel production 3Team overcomes major obstacles to cellulosic biofuel production 4Standardized protocols would greatly enhance clinical and research potential of BTMs 2
... include: 5 gasket slides/kit Gasket slide kit ... or Gasket ... set of disposable gasket slides offered in either 11K ... microarray formats. The gaskets are carefully fabricated and ...
... Polyclonal Antibody, Unconjugated ... a dilution of 1/100. IP: Use ... Use at an assay dependent dilution. ... tested in other applications. Optimal ...
... offers an intuitive, easy-to-use operating ... diverse data handling, and integration ... functions include data acquisition, re-analysis, ... in both standalone and network ...
This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
Biology Products: